<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660920</url>
  </required_header>
  <id_info>
    <org_study_id>AP24534-07-101</org_study_id>
    <nct_id>NCT00660920</nct_id>
  </id_info>
  <brief_title>Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies</brief_title>
  <official_title>A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose or a recommended dose of
      oral AP24534 in a defined schedule in patients with refractory or advanced chronic
      myelogenous leukemia and other refractory hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2008</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Maximum Tolerated Dose (MTD) or Recommended dose</measure>
    <time_frame>Up to</time_frame>
    <description>Determine MTD dose or a recommended dose of oral ponatinib in a defined schedule (QD) in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the safety of AP24534 in patients with resistant/refractory hematologic malignancies</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the anti-tumor activity of AP24534 in patients with refractory hematologic malignancies</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the pharmacokinetics of AP24534</measure>
    <time_frame>Up to 2 cycles (1 cycle = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine pharmacodynamic activity of AP24534 in CML and Ph + ALL patients</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe potential pharmacogenomic markers of AP24534 anti-tumor activity</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>ponatnib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparison of different dosages of ponatinib given orally once per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Comparison of different dosages of drug given orally once per day.</description>
    <arm_group_label>ponatnib</arm_group_label>
    <other_name>AP24534</other_name>
    <other_name>Iclusig</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female ≥ 18 years old

          -  Diagnosed hematologic malignancy (other than lymphoma) that has relapsed or is
             refractory to standard care or for which no standard care is available or acceptable

          -  Able to give written informed consent

          -  ECOG performance status ≤ 2

          -  BSA ≥ 1.5 m² (first cohort only)

          -  Minimum life expectancy of 3 months or more

          -  Adequate renal function defined as serum creatinine &lt;1.5× upper limit of normal (ULN)
             for institution

          -  Adequate hepatic function (defined as: Total bilirubin &lt;1.5 × ULN for institution; ALT
             and AST &lt;2.5 × ULN for institution [&lt;5 X ULN if liver involvement with leukemia];
             Prothrombin time &lt;1.5 × ULN)

          -  Ability to comply with study procedures in the Investigator's opinion

          -  Adequate cardiac function defined as ejection fraction (EF) &gt;40% by any method of the
             investigator's choice

          -  Normal QTcF interval on screening ECG evaluation, defined as QTcF of &lt;450 ms.

          -  For females of childbearing potential, a negative pregnancy test must be documented
             prior to enrollment

          -  Female patients who are of childbearing potential must agree to use an effective form
             of contraception with their sexual partners throughout participation in this study

        Exclusion Criteria:

          -  Have had cytotoxic chemotherapy or radiotherapy within 21 days prior to entering the
             study, or those who have not recovered from adverse events due to agents administered
             more than 28 days earlier with the exception of alopecia

          -  Received any other investigational agents or have received an investigational agent
             within 14 days of starting ponatinib

          -  Malabsorption syndrome or other illness which could affect oral absorption

          -  Significant uncontrolled cardiac disease

          -  Patients taking medicinal products that are known to be associated with prolongation
             of the QT interval on the electrocardiogram.

          -  Uncontrolled hypertension (Diastolic BP &gt;100 mmHg; Systolic &gt;150 mmHg)

          -  Uncontrolled intercurrent illness

          -  Pregnant

          -  Known infection with HIV

          -  Autologous or allogeneic stem cell transplant &lt; 3 months prior to enrollment; any
             evidence of ongoing graft versus host disease (GVHD), or GVHD requiring
             immunosuppressive therapy

          -  Another primary malignancy within the past 3 years

          -  Any condition or illness which, in the opinion of the investigator, would compromise
             patient safety or interfere with the evaluation of the safety of the drug

          -  Patients taking medicinal products that are known to be associated with prolongation
             of the QT interval on the electrocardiogram

          -  Major surgery (with the exception of intravenous catheter placement or bone marrow
             biopsy) within 14 days prior to initiating ponatinib therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ARIAD Investigational Site #075</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARIAD Investigational Site #011</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARIAD Investigational Site #048</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARIAD Investigational Site #076</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARIAD Investigational Site #005</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>70030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

